IMVARIA adds InVision’s cardiac amyloid AI to AI Lab

IMVARIA will offer InVision Medical Technology’s FDA-cleared Precision Cardiac Amyloid tool through its AI Lab, making the echocardiography algorithm available to clinicians on a referral basis. The move expands access to a test designed to flag possible cardiac amyloidosis earlier, before patients are sent for confirmatory testing.

Why it matters: - Cardiac amyloidosis is still widely underdiagnosed. - Earlier detection can speed confirmatory testing and give patients more time to benefit from approved therapies for ATTR-CM. - IMVARIA’s referral-based model makes the AI available to clinicians who do not have the software built into their own imaging systems.

What happened: - InVision Medical Technology and IMVARIA announced that IMVARIA’s AI Lab will offer Precision Cardiac Amyloid, InVision’s FDA-cleared AI for detecting cardiac amyloidosis from echocardiograms. - IMVARIA’s AI Lab is the first diagnostic service to offer the algorithm on a referral basis. - Clinicians can order the test through IMVARIA’s AI Lab. - The service is designed for use by treating physicians through an independent diagnostic testing facility model.

The details: - Precision Cardiac Amyloid received FDA 510(k) clearance in May 2025 for adults aged 65 and older. - The algorithm runs on routine echocardiograms. - The software alerts the interpreting physician when a patient should be referred for confirmatory testing. - IMVARIA already offers Fibresolve, an FDA-cleared AI adjunctive diagnostic service for lung fibrosis. - IMVARIA also offers ScreenDx, an FDA-cleared AI technology authorized to assess findings compatible with interstitial lung disease. - IMVARIA was founded in 2019 by physician-engineers from Google and Stanford University. - IMVARIA is based in Berkeley, California. - InVision Medical Technology focuses on improving the precision and accuracy of cardiovascular imaging. - InVision is backed by Y Combinator.

Between the lines: - The partnership gives InVision a distribution path that resembles a standard send-out lab test, which may be easier for clinicians to adopt than embedded software inside imaging systems. - The announcement targets a common diagnostic gap: echocardiograms are often the first cardiac imaging study, but amyloid findings can be overlooked when symptoms resemble more common heart conditions. - InVision framed the tool as a way to help clinicians identify patients earlier for additional evaluation, while IMVARIA framed the service as an expansion of access.

What's next: - Clinicians can begin ordering the cardiac amyloid AI through IMVARIA’s AI Lab. - The companies are positioning the workflow for broader use in referral-based diagnostic testing. - The announcement suggests both companies are continuing to build out AI diagnostics for cardiovascular and other disease areas.

The bottom line: - IMVARIA is turning InVision’s cardiac amyloid AI into a send-out diagnostic service, aiming to widen access and catch more cases before diagnosis is delayed.